145 related articles for article (PubMed ID: 7907237)
1. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
Lothstein L; Hosey LM; Sweatman TW; Koseki Y; Dockter M; Priebe W
Oncol Res; 1993; 5(6-7):229-34. PubMed ID: 7907237
[TBL] [Abstract][Full Text] [Related]
2. N-benzyladriamycin-14-valerate and drug resistance: correlation of anthracycline structural modification with intracellular accumulation and distribution in multidrug resistant cells.
Lothstein L; Wright HM; Sweatman TW; Israel M
Oncol Res; 1992; 4(8-9):341-7. PubMed ID: 1362503
[TBL] [Abstract][Full Text] [Related]
3. Resistance to N-benzyladriamycin-14-valerate in mouse J774.2 cells: P-glycoprotein expression without reduced N-benzyladriamycin-14-valerate accumulation.
Lothstein L; Sweatman TW; Dockter ME; Israel M
Cancer Res; 1992 Jun; 52(12):3409-17. PubMed ID: 1350753
[TBL] [Abstract][Full Text] [Related]
4. Cellular resistance against the novel hybrid anthracycline N-(2-chloroethyl)-N-nitrosoureidodaunorubicin (AD 312) is mediated by combined altered topoisomerase II and O6-methylguanine-DNA methyltransferase activities.
Pawlik CA; Israel M; Sweatman TW; Lothstein L
Oncol Res; 1998; 10(4):209-17. PubMed ID: 9778692
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity and intracellular biotransformation of N-benzyladriamycin-14-valerate (AD 198) are modulated by changes in 14-O-acyl chain length.
Lothstein L; Rodrigues PJ; Sweatman TW; Israel M
Anticancer Drugs; 1998 Jan; 9(1):58-66. PubMed ID: 9491793
[TBL] [Abstract][Full Text] [Related]
6. Cross-resistance to diverse drugs is associated with primary cisplatin resistance in ovarian cancer cell lines.
Hamaguchi K; Godwin AK; Yakushiji M; O'Dwyer PJ; Ozols RF; Hamilton TC
Cancer Res; 1993 Nov; 53(21):5225-32. PubMed ID: 8106143
[TBL] [Abstract][Full Text] [Related]
7. Resistance to anthrapyrazoles and anthracyclines in multidrug-resistant P388 murine leukemia cells: reversal by calcium blockers and calmodulin antagonists.
Klohs WD; Steinkampf RW; Havlick MJ; Jackson RC
Cancer Res; 1986 Sep; 46(9):4352-6. PubMed ID: 3460695
[TBL] [Abstract][Full Text] [Related]
8. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
9. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
[TBL] [Abstract][Full Text] [Related]
10. Selective enhancement of vincristine cytotoxicity in multidrug-resistant tumor cells by dilantin (phenytoin).
Ganapathi R; Hercbergs A; Grabowski D; Ford J
Cancer Res; 1993 Jul; 53(14):3262-5. PubMed ID: 8100737
[TBL] [Abstract][Full Text] [Related]
11. Circumvention of P-GP MDR as a function of anthracycline lipophilicity and charge.
Lampidis TJ; Kolonias D; Podona T; Israel M; Safa AR; Lothstein L; Savaraj N; Tapiero H; Priebe W
Biochemistry; 1997 Mar; 36(9):2679-85. PubMed ID: 9054575
[TBL] [Abstract][Full Text] [Related]
12. Apoptosis induced by anthracycline antibiotics in P388 parent and multidrug-resistant cells.
Ling YH; Priebe W; Perez-Soler R
Cancer Res; 1993 Apr; 53(8):1845-52. PubMed ID: 8467504
[TBL] [Abstract][Full Text] [Related]
13. Further examination of 9-alkyl- and sugar-modified anthracyclines in the circumvention of multidrug resistance.
Coley HM; Twentyman PR; Workman P
Anticancer Drug Des; 1992 Dec; 7(6):471-81. PubMed ID: 1337431
[TBL] [Abstract][Full Text] [Related]
14. Cross resistance relevance of the chemical structure of different anthracyclines in multidrug resistant cells.
Tapiero H; Nguyen-Ba G; Lampidis TJ
Pathol Biol (Paris); 1994 Apr; 42(4):328-37. PubMed ID: 7808786
[TBL] [Abstract][Full Text] [Related]
15. The 95-kilodalton membrane glycoprotein overexpressed in novel multidrug-resistant breast cancer cells is NCA, the nonspecific cross-reacting antigen of carcinoembryonic antigen.
Ross DD; Gao Y; Yang W; Leszyk J; Shively J; Doyle LA
Cancer Res; 1997 Dec; 57(24):5460-4. PubMed ID: 9407950
[TBL] [Abstract][Full Text] [Related]
16. Chemoresistance to doxorubicin and cisplatin in a murine cell line. Analysis of P-glycoprotein, topoisomerase II activity, glutathione and related enzymes.
Mestdagh N; Pommery N; Saucier JM; Hecquet B; Fournier C; Slomianny C; Teissier E; Hénichart JP
Anticancer Res; 1994; 14(3A):869-74. PubMed ID: 7915509
[TBL] [Abstract][Full Text] [Related]
17. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
18. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines.
Dong J; Naito M; Tatsuta T; Seimiya H; Johdo O; Tsuruo T
Oncol Res; 1995; 7(5):245-52. PubMed ID: 8534930
[TBL] [Abstract][Full Text] [Related]
19. Scytophycins, novel microfilament-depolymerizing agents which circumvent P-glycoprotein-mediated multidrug resistance.
Smith CD; Carmeli S; Moore RE; Patterson GM
Cancer Res; 1993 Mar; 53(6):1343-7. PubMed ID: 8095179
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
